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COLPOSCOPIC AND CYTOLOGICAL CHANGES IN 
INTRAUTERINE CONTRACEPTIVE DEVICE USERS – A 
PROSPECTIVE STUDY
INTRODUCTION
Intrauterine Contraceptive Device (IUD) is a safe, convenient and inexpensive 
method  of  contraception  involving  neither  repetition  nor  interference  with  sexual 
activity 2.
In India, IUD is the second most commonly used family planning method after 
voluntary female sterilization 1.
IUD has its own merits and demerits.
The various complications related to IUD use are.
Immediate
Difficulty in insertion
Vasovagal attack
Uterine Cramps
Early
Expulsion
Perforation
Spotting
Menorrhagia
Dysmenorrhea
Vaginal Infection
Actinomyces
Late
Pelvic Inflammatory disease
Pregnancy
Ectopic Pregnancy 3
Various studies have been conducted since 1980 to study the long-term effect of 
IUD and its role in predisposition to cervical or endometrial pathology.
The  studies  involve  clinical  examination,  Cytology,  Colposcopy  and 
histopathology for detection of cervical pathology.
Colposcopic examination involves the systematic evaluation of the lower genital 
tract  with  special  emphasis  on  the  superficial  epithelium  and  blood  vessels  of  the 
underlying connective tissue stroma.
Cytological study is by means of papsmear.
Presently  exfoliative  cytology  and  colposcopy  are  considered  to  be 
complementary  to  each  other  in  the  detection  of  early  neoplastic  changes.   These 
procedures  have contributed to  the  lowering  of  incidence of  invasive  cancer  of  the 
cervix in the developed world.
AIM OF THE STUDY
To  compare  the  colposcopic  changes  and  cytological  changes  found  in 
intrauterine contraceptive device users 
To create awareness among the IUD users for regular follow up 
REVIEW OF LITERATURE
Intra  uterine  contraceptive  devices  are  an  effective,  safe  and  convenient 
contraceptive method.  They are particularly suitable for women who,
1) Are breast feeding.
2) Have difficultly in using other reversible methods.
3) Prefers a method that does not require supervision or action before sexual 
intercourse.
4) Those in whom other methods are contraindicated.2
The  intrauterine  device  as  a  contraceptive  method  for  women  was  first 
introduced by German Physician Richard Richter in 1909 the device was ring shaped 
and was made of silkworm gut. 1, 2.
Lippes loop and margulies coil were the first widely used plastic IUDS.  The 
lippes loop is marketed since 1962. 1, 2.I . In India Lippes loop was introduced in National 
Family Planning Programme in 1965 at its second world conference in 1964, Population 
council, studied various critical event of IUDs, and it was concluded that IUD was a 
safe  and  effective  method  of  contraception,  appropriate  for  use  in  national  family 
planning programmes 2. 
The first medicated devices were developed by James Zipper and Howard Tatum 
in 1969.  The addition of copper improved the quality of IUD’s 1, 2.. In 1970 s ,Cu T 200 
was introduced in National Family Planning Programme in India Since 1973,  IUDS 
containing hormone are being developed progestasert,  a hormone releasing IUD was 
first marketed in 1974 2  with a view to reduce the chance of expulsion after insertion in 
the immediate post partum period, anchoring IUDS of different models with various 
fixation systems are being tried. 1, 2.
DISTRIBUTION
IUD users world wide, 130 million (WHO 2000)
IUD users in India, 7.4 million (1999)
No. of IUD insertions at KGH  - 1450 /  year (2002-2006)
MECHANISM OF ACTION
1. Presence  of  a  foreign  body  in  the  uterine  cavity  renders  the  migration  of 
spermatozoa difficult.
2. A foreign body within the uterus provides uterus contractility and increase the 
tubal peristalsis, so that the fertilized egg is propelled along the fallopian tube 
more  rapidly  than  in  normal  and  it  reaches  the  uterine  cavity  before  the 
development of chorionic villi and thus is unable to implant.
3. The  device  in  situ  causes  leucocytic  infiltration  in  the  endometrium.  The 
macrophages engulf the fertilized egg.
4. Copper  T elutes  copper  which  brings  about  certain  enzymatic  and metabolic 
changes in the endometrial tissue which are inimical to the implantation of the 
fertilized egg. 1, 2,  3.
Types of IUDs and its Effective life 2
S. No Name of The Device Effective Life of IUD
Pregnancy Rate/100 
women years
1.
Inert IUD 
Lippes Loop
Greater than 2/100 
women year.
II. Copper Releasing  IUD
1. Copper 7 3 Years Greater than 2/100 women year.
2. Copper T 200 4 Years Greater than  2/100 women year.
3. Multi load Cu 250 3 Years
Less than 2 / 100 but 
more than 1 /100 
women year.
4. Multi load Cu 375 5 Years -do-
5. Nova Cu T 200 5 Years -do-
6. Copper T 220  3 Years -do-
7. Cu T 380 D 10 Years Less than 0.5 / 100 women years
8. Cu T 380 Ag. 4 Years -do-
9. Cu T 380 S 2.5 Years
-do-
III. Hormone Releasing IUD
1. Progestasert 1 year Less than 0.5/100 women year
2. Levonorgesterol IUD 20 5 Years -do-
MEDICAL ELIGIBILITY CRITERIA FOR REVERSIBLE 
CONTRACEPTIVES
Category I No restriction of use
Category II Advantages of using the method outweigh the theoretical or proven risks
Category III Theoretical or proven risks outweigh the advantages of using the method. 
Should be used only when alternative methods of contraception are 
not acceptable by the client and they need careful supervision
Category IV Use of the method presents acceptable health risks
ELIGIBLE CRITERIA FOR INITIATING INTRAUTERINE 
DEVICE USE
Cu-IUD  = Copper – Bearing IUD
LNG-IUD = Levonorgestrel – Releasing IUD (20ug /24hours)
INTRAUTERINE
DEVICES (IUDS)
IUDS do not  protect  against  STI/HIV.   If  there  is  risk of  STI/HIV 
(including the  postpartum period),  the  correct  and consistent  use  of 
condoms is recommended, either alone or with another contraceptive 
method.  Male latex condoms are proven to protect against STI/HIV).
CONDITION CATEGORY CLARIFICATIONS/ EVIDENCE
Cu-IUD LNG- IUD
PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY
PREGNANCY 4 4
Clarification:  The  IUD  is  not  indicated 
during pregnancy and should not be used 
because  of  the  risk  of  serious  pelvic 
infection and septic spontaneous abortion.
AGE
a) Menarche to 
< 20 years
b)   >20 years
2
1
2
1
Due  to  more  chances  of  expulsion  in 
nullipara and risk of STI’s due to sexual 
behaviours in younger age.
CONDITION CATEGORY CLARIFICATIONS/ EVIDENCE
Cu-IUD LNG- IUD
PARITY
a) Nulliparous
b) Parous
2
1
2
1
Evidence: There are conflicted data 
regarding whether IUD use is associated 
with infertility among nulliparous women, 
although recent,well-conducted studies 
suggest no increased risk.
POSTPARTUM
(Breastfeeding or 
non-breastfeeding, 
including post-
caesarean section)
a) <48 Hours
b) 48 hours to <4 
weeks 
c) >   4 weeks 
d) Puerperal 
sepsis
2
3
1
4
3
3
1
4
Evidence:  There  was  some  increase  in 
expulsion  rates  with  delayed  postpartum 
insertion compared to immediate insertion 
and with immediate  postpartum insertion 
compared to interval insertion
POST – 
ABORTION
a) First Trimester 
b) Second 
trimester
c) Immediate 
Post-septic 
abortion
1
2
4
1
2
4
Clarification:  IUDs  can  be  inserted 
immediately  after  first  –trimester, 
spontaneous or induced abortion.
Evidence: There was no difference in risk 
of  complications  for  immediate  versus 
delayed insertion of an IUD after abortion. 
Expulsion was greater when an IUD was 
inserted  following  a  second  –trimester 
abortion versus following a first-trimester 
abortion.  There  were  no  differences  in 
safety  or  expulsions  for  post-abortion 
insertion of an LNG-IUD compared with 
Cu-IUD.
PAST ECTOPIC 
PREGNANCY 
1 1
SMOKING 1 1
OBESITY
> 30 kg/m2 body 
mass index (BMI)
1 1
CONDITION CATEGORY CLARIFICATIONS/ EVIDENCE
Cu-IUD LNG- IUD
Hypertension
a) Adequately 
controlled 
hypertension where 
blood pressure can be 
evaluated
b) Elevated blood 
pressure levels 
(Property taken 
measurements)
1
1
1
2
DEEP VENOUS 
THROMBOSIS 
(DVT) / 
PULMONARY 
EMBOLISM (PE)
a) History of 
DVT/PE
1 2
ISCHAEMIC 
HEART DISEASE
1 2
STROKE 1 2
KNOWN 
HYPERLIPIDAEMI
AS
1 2 Clarification:  Routine  screening  is  not 
appropriate  because  of  the  rarity  of  the 
conditions and the high cost of screening.
VALVULAR 
HEART DISEASE
a) Uncomplicated 
b) Complicated 
1
2
1
2
Clarification:  Prophylactic  antibiotics  to 
prevent  endocarditis  are  advised  for 
insertion.
HEADACHES
a) Non-
migrainous
b) Migraine
1
1
1
2
Clarification:  Any  new  headaches  or 
marked  changes  in  headaches  should  be 
evaluated.
CONDITION CATEGORY CLARIFICATIONS/ EVIDENCE
Cu-IUD LNG- IUD
VAGINAL 
BLEEDING 
PATTERNS
a. Irregular Pattern 
without heavy 
bleeding
b. Heavy or 
prolonged bleeding 
(includes regular and 
irregular patterns)
1
2
1
1
Clarification: Unusually heavy bleeding 
should raise the suspicion of a serious 
underlying condition.
Evidence: Among women with heavy or 
prolonged bleeding, LNG-IUDs were 
beneficial in treating menorrhagia
UNEXPLAINED 
VAGINAL 
BLEEDING
(Suspicion for 
serious condition)
Before evaluation
4 4 Clarification:  If  pregnancy  or  an 
underlying pathological condition (such as 
pelvic malignancy) is suspected, it must be 
evaluated and the category adjusted after 
evaluation.  There  is  no need to   remove 
the IUD before evaluation.
ENDOMETRIOSIS 2 1 Evidence:  LNG-IUD  use  among  women 
with  endometriosis  decreased 
dysmenorrhoea and pelvic pain
BENIGN OVARIAN
TUMOURS
(INCLUDING 
CYSTS)
1 1
SEVERE
DYSMENORRHOEA 2 1
TROPHOBLAST
DISEASE
Benign gestational
Trophoblasticdisease 
Malignant gestational
Trophoblastic disease
3
4
3
4
CERVICAL 
ECTROPION 1 1
CERVICAL 
INTRAEPITHELIAL 
NEOPLASIA (CIN)
1 2
CONDITION CATEGORY CLARIFICATIONS/ EVIDENCE
Cu-IUD LNG- IUD
CERVICAL 
CANCER
(Awaiting treatment)
4 4
ENDOMETRIAL 
CANCER
4 4 
 
OVARIAN 
CANCER
3 3       
UTERINE 
FIBROIDS
a) Without distortion 
of the uterine 
cavity
b) With distortion of 
the uterine cavity.
1
4
1
4
Evidence:  Among  women  with  fibroids, 
there were no adverse health events with 
LNG-IUD use and there was a decrease in 
symptoms  and  size  of  fibroids  for  some 
women.
ANATOMICAL 
ABNORMALITIES
a) Distorted uterine 
cavity 
b) Other 
abnormalities not 
distorting the uterine 
cavity or interfering 
with IUD insertion
4
2
4
2
PID
a) Past PID 
With subsequent 
pregnancy
b) Past PID 
Without subsequent 
pregnancy
c) PID Current
1
2
4
1
2
4
CONDITION CATEGORY CLARIFICATIONS/ EVIDENCE
Cu-IUD LNG- IUD
STI
a.Current Purulent 
cervicitis or 
chlamydial infection 
or gonorrhoea
b.Other STI s 
(excluding HIV and 
hepatitis)
c.Vaginitis (including 
trichonomonas 
vaginalis and 
bacterial vaginosis
d.Increased risk of 
STIs
4
2
2
2
4
2
2
2
HIV
a.High Risk of HIV
b.HIV Infected
cAIDS
d.Clinically well on 
ARV therapy
3
3
3
2
3
3
3
2
Tuberculosis
a.Non Pelvic
b.Known Pelvic
1
4
1
4
Diabetes 1 2
Thyroid Disorders 1 1
Gall Bladder Disease 1 2
Anaemias 2 1
Drugs which affect 
liver enzymes
1 1
Antibiotics 1 1
Timing of IUD Insertion
1) During or soon after menstruation  1, 2.
2) Post abortal Insertion
There  is  5  –10  times  more  chance  of  expulsion  of  the  IUD  when  inserted 
immediately after second trimester abortion.  It is better to wait for 4 weeks or till the 
next period which ever is earlier (WHO task force study, 1985).  2.
3) Postpartum Insertion
Following caesarean section it  is  better to introduce IUD after 1-3 months of 
delivery. The disadvantage of immediate postpartum insertion of the IUD is its higher 
expulsion  rate  and uterine  perforation.  Most  authorities  advocate  insertion  after  4-6 
weeks of delivery (WHO, Intrauterine device, 1997).
4) Insertion in Lactating women
An IUD can be safely inserted in lactating women because it does not alter the 
quantity and composition of breast milk (WHO, 1987), chance of pregnancy must be 
excluded before an IUD is inserted 1, 2.
KEY POINTS IN PATIENT COUNSELLING
1. Protection against unwanted pregnancy begins immediately after insertion.
2. Menses can be longer and heavier.
3. There is a slightly increased risk of pelvic infection in the first few months after 
insertion.
4. Protection against infections transmitted through the vaginal mucosa requires the 
use of condoms.
5. Ectopic pregnancies can still occur.
6. The IUD can be spontaneously expelled. Frequent palpation of the IUD strings, 
especially following menstruation is important to avoid unwanted pregnancies. 
If the strings are not felt or something hard is palpable (Suggestive of the IUD 
frame) medical advice should be immediately sought1, 2.
Technique of Insertion
The person who is going to insert a device requires some training in accurate 
pelvic  examination  and  in  gentle  insertion  of  the  device.  A  thorough  pelvic 
examination is  performed to  determine the position and size of  the uterus.   The 
presence of any uterine, tubal or ovarian pathology precludes the insertion of the 
device.  The vagina and cervix are inspected by means of a speculum.  Any vaginal 
or cervical  infection must be treated and cured before a device is inserted.   The 
cervix is grasped with a vulsellum or allis forceps.  The device with the introducer is 
available in a pre-sterilized pack.  The device is mounted into the introducer, and the 
stop on the introducer is adjusted to the length of the uterine cavity.  The introducer 
is then passed through the cervical canal and the device is inserted by withdrawing 
the plunger over the outer sheath 2, 3.
Advantages of IUD
1) Coital independent
2) There is no problem of disposal affecting privacy.
3) There are no systemic ill  effects,  unlike oral  contraceptive pills  4 ,no adverse 
effect on lactation is observed.
4) There  is  no  evidence  of  reduced  fertility  following  its  removal.  About  75% 
women conceive within 6 months of its removal and almost 90% conceive within 
a year 2, 3.
COMPLICATIONS AND THEIR MANAGEMENT
Increased Bleeding
An increase of 20-30% of mean menstrual blood loss has been found by most 
studies  (Newton  1993),  2.  The  symptoms  most  often  responsible  for  IUD 
discontinuation  are  increased  uterine  bleeding  and  increased  menstrual  pain  and 
removal rate is 2-10 per 100 users in the first year (Population Report, 1988) 2.  
Inter menstrual bleeding in the form of spotting also occurs 1, 2.
The cause of increased bleeding is not definitely known and thought to be due to.
1) Increased production of plasminogen – activating enzymes leading to lysis of 
fibrin of blood clot.
2) Increased vascularity of the endometrium.
3) Hormonal asynchronization, because menstruation is advanced by about 2 days 
before the end of luteal phase when the level of progesterone still remains relatively 
high (Brenner & Mishell, 1975) 2
Non steroidal anti-inflammatory agents if administered from the onset of menses 
and maintained for  3  days,  reduce heavy bleeding and pain (Speroff  & Darney, 
1996, Guillebaud, 1999) 2 Iron supplement should be given for 3 months or more if 
the bleeding makes the patient anaemic.
Pain
Pain is usually due to uterine cramp, it subsides within a week and is mostly 
relieved by analgesic  and NSAIDS.  Persistent pelvic pain may be due to abnormal 
position of the IUD, uterine Perforation, the beginning of the expulsion of the IUD, 
disparity between IUD size and cavity size, associated PID or ectopic pregnancy. 
Hence persistent pain should be investigated and often needs removal of the IUD 2.
Expulsion
Approximately 5% of patients expel IUD with in the first year 1, 2.
Expulsion occurs more often in nulliparous and younger women than those over 
30  1,  2.  This event can be associated with cramping,  vaginal  discharge,  or uterine 
bleeding.  However, in some cases, the only observable change is lengthening or 
absence  of  the  IUD strings.   Patients  should  be  cautioned to  request  immediate 
attention if expulsion is suspected.
Perforation
Perforation occurs rarely, not more than 1.2 per 100 insertions as has been found 
in large clinical trails (WHO, 1982) 2 More recent Studies involving newer devices 
of  group II  & Group III  such as ML CU250,  CUT 380 A, have found that  the 
incidence of uterine perforation is  less  than 1 per 3000 insertions (Edelman and 
vanor,  1990),  2 .The  devices  may  migrate  into  the  peritoneal  cavity  or  become 
embedded  in  the  uterine  musculature.  Most  perforations  occur  at  the  time  of 
insertion owing to faulty techniques.  Perforation occur mostly without symptoms 
and thus sometimes remain undiagnosed for a long time.  However, sharp pain at the 
time of  insertion,  disappearance of  the  tail  and post  –  insertion  bleeding are  all 
features of perforation.  2.
PELVIC INFLAMMATORY DISEASE
IUD – Related bacterial infection is now believed to be due to contamination of 
the endemetrial cavity at the time of insertion.   Mishells classic study indicated that 
the uterus is routinely contaminated by bacteria at insertion 4,1.
Infections that occur 3-4 months after insertion are believed to be due to acquired 
STI’s  1,2
The early,  insertion related infections,  is  polymicrobial  and are derived from the 
endogenous cervico vaginal flora, with a predominance of anaerobes.
A WHO review of 12 studies involving nearly 23,000 IUD users worldwide found 
that the overall prevalence of PID among IUD users is 1.6 cases per 100 women years 
of use (WHO, 1997). However PID is more during the first 20 days of insertion (9.7 
cases per 100 women years of use) 5 ,1
The problem of infection can be minimized with careful screening and the use of 
aseptic technique 1, 2
Doxycycline 200 mg or Azithromycin 500 mg administered orally one hour prior to 
insertion  can  provide  protection  against  insertion-associated  pelvic  infection,  but 
prophylatic  antibiotics  are  probably  of  little  benefit  for  women  at  low  risk  of 
STI’s 6, 1, 2, 7
Antibiotic prophylaxis (Amoxicillin 2g) should be provided before the insertion or 
removal  for  the  women  who  are  at  increased  risk  of  bacterial  endocarditis  .  1 
Aysmptomatic  IUD  users  whose  cervical  culture  show  gonorrheal  or  chlamydial 
infection should be treated with recommended drugs without removal of the IUD. If 
however  there  is  evidence  that  an  infection  has  ascended  to  the  endometrium  or 
fallopian tubes treatment must be instituted and IUD removed properly 1
Leucorrhoea
There is increased incidence of Leucorrhoea in IUD users. Higher frequency of 
Trichomonas  vaginalis  and coryne  bacterium vaginalis  was  found in  IUD users  8  ,9. 
There  is  no  evidence  that  prevalence  of  bacterial  vaginosis  is  influenced  by  IUD 
use 10, 9, 1 vaginal bacteriosis should be treated with metronidazole 500 mg bid for 7 days. 
But the IUD need not be removed unless pelvic inflammation is present.
Actinomyces
The significance of actinomycosis infection in IUD users is unclear. There are many 
reports  of  IUD users  with unilateral  pelvic abscess containing gram positive bacilli, 
Actinomyces  11,12,13 However,  Actinomyces,  part  of  the  normal  flora  in  the  gastro 
intestinal  tract  are  found  in  pap  smears  of  upto  30%  of  plastic  IUD  users  when 
cytologists take care to look for the organisms. The rate is much lower (less than 1%) 
with copper devices and varies with duration of use 12,14,15. Further more, Actinomyces 
are commonly present in the normal vagina 16.      
The clinician must decide whether to remove the IUD and treat the patient, treat with 
the  IUD  in  place,  or  simply  remove  the  IUD.  These  patients  are  almost  always 
asymptomatic and without clinical signs of infection. If uterine tenderness or a pelvic 
mass is present, the IUD should be always be removed after the initiation of treatment 
with  oral  penicillin  G  500  mg  that  should  be  continued  for  a  month.  Alternative 
antibiotic regimens include tetracycline 500 mg, doxycycline 100 mg bid, amoxicillin / 
clavulanate  500  mg  bid.  If  actinomyces  are  present  on  the  pap  smear  of  an 
asymptomatic woman, in our view it is not necessary to administer antibiotic treatment 
or to remove the IUD.
Although it  has  been  recommended that  the  IUD should  be  removed in  this 
instance and replaced when a repeat  Pap smear is  negative,  there is  no evidence to 
support  this  recommendation.  Another  anaerobic  gram  positive  rod,  Eubacterium 
nodatum,  resembles  actinomyces  and  has  also  been  reported  to  be  associated  with 
colonization of an IUD 17. E. nodatum can be mistaken for actinomyces on papsmears. 
Our recommendations can be applied to both E-nodatum and actinomyces. (1)
Pregnancy
IUDs can be divided into three groups according to the pregnancy rate indicating 
their contraceptive efficiency (WHO, 1987).
Group I-Pregnancy rates greater than 2 / 100 women years
Lippes loop, cu 7, cu T 200.
Group II-Pregnancy rates less than 2 / 100 but more than 1 / 100 women years.
Nova T, Multi load Cu 250 and Cu T 220c.
Group III-Pregnancy rates less than 1 (Mostly less than 0.5 / 100 women years)
Cu T 380 A, Cu T 380 S, ML Cu 375 and LNG 20.
As soon as pregnancy is confirmed the IUD should be removed (WHO 1997), if 
it can be done easily, to reduce the risk of pelvic infection and miscarriage the most 
frequent complication of pregnancy with an IUD in place. If the removal is not possible 
easily, the woman should be informed of the increased risks of infection, miscarriage 
and premature labour.  She may be offered termination of pregnancy where the laws 
permit as in India (IPPF, 1987).
There is however, no evidence at all that the pregnancy is more likely than usual 
to result in an infant with congenital malformations if IUD’s, including copper devices, 
are left insitu. 2
Ectopic Pregnancy
The chance of ectopic pregnancy in IUD users is rare and ranges from 0.25 -1.5 / 
1000 women years (Sivin et al 1987). However when pregnancy occurs, the chances of 
ectopic pregnancy is higher (about 30%) than in general population (about 0.5 to 0.8%) 
of all pregnancies. This complication can be reduced by avoiding IUD in cases with 
previous PID, previous ectopic pregnancy and in those who have multiple sex partners.
COLPOSCOPIC AND CYTOLOGICAL CHANGES IN 
INTRAUTERINE DEVICE USERS
Cytological changes associated with intrauterine device users are evaluated in 
many studies.
The various changes associated with presence of intrauterine device include
-Inflammation
-Hyperplasia
-Papillary proliferation of endocervical epithelium
-Multi nucleation
-Increased squamous metaplasia.
Because of the mechanical effect of intrauterine device, atypical glandular cells 
mimicking  adenocarcinoma  and  atypical  squamous  cells  mimicking  squamous  intra 
epithelial lesion may be seen. Atypical squamous cells of undetermined significance 
(ASCUS) is seen in 1.6% and atypical glandular cells in 1.6% cases.
In these cases the changes disappeared in a period of 3 to 4 months after removal 
of  the  intrauterine  device.  One  should  be  careful  because  of  the  difficult  diagnosis 
between reactive cytomorphological changes and dysplastic or neoplastic process in a 
cervico vaginal smears of intrauterine device users. 26
Study by Fiore N - in 1986, showed suspect colposcopic signs were frequently 
associated with the use of IUD. The Oncologic evaluation of smears showed a slight 
dysplasia in 17.65% of IUD users 8.
Non specific inflammatory changes are found frequently in Lippes loop and Cu T 
200 users (27), (9)
Only long term cytological follow up in controlled studies can rule out Carcinogenic 
effects of IUDs especially for copper IUDs Close cervical examination when inserting 
the IUD, including cytology, colposcopy and biopsy is recommended 29
Although abnormal uterine bleeding in IUD users is common, the health professionals 
should not ignore the symptom of menorrhagia and always exclude the possibility of 
malignancy 30.
THE PAPANICOLAOU SMEAR TERMINOLOGY IN 
CERVICAL CYTOLOGY - THE BETHESDA SYSTEM
 
The introduction of evaluation of cellular material from the cervix and vagina for 
the diagnosis of cervical carcinoma is generally attributed to George Papanicolaou
Pap smear nomenclature
Papanicolaou
Class system
(1954)
Descriptive
(1968)
CIN 1978
(Cervical intra 
epithelial 
neoplasia)
Bethesda system 
(1988)
Class I -Negative for
malignant cells
Negative Within normal limits
Class II -Inflammatory 
atypia
-Squamous atypia
-Koilocytic atypia Negative
Inflammatory 
Reparative changes
Atypical squamous 
cells of undetermined 
significance
Class III Mild dysplasia
Moderate 
dysplasia
Severe dysplasia
CIN-I
CIN-II
CIN-III
-Low grade squamous 
Intraepithelial lesion
High grade squamous 
intraepithelial lesion 
(HSIL)
HSIL
Class IV Carcinoma insitu CIN-III HSIL
Class V Invasive carcinoma
Invasive 
carcinoma Invasive carcinoma
BETHESDA SYSTEM FOR REPORTING CERVICAL / 
VAGINAL CYTOLOGIC DIAGNOSIS (2001) REVISION
General Categorization
1) Within Normal limits
2) Benign cellular changes
3) Epithelial cell abnormality
Benign Cellular Changes (BCC)
Infection and reactive or reparative changes are included under the category of BCC
INFECTION (10% OF CASES)
1) Trichomonas  vaginalis-  Positive  predictive  value  of  40% in  an  average  risk 
population
2) Candida - Sensitivity of pap smear compared with culture is about 50%
3) Predominance of coccobacilli consistent with the shift in vaginal flora-suggestive 
of bacterial vaginosis.
4) Bacteria morphologically consistent with actinomyces species
They  are  best  recognized  on  cytological  smear  by  branching  gram-positive 
filaments their presence is strongly associated with presence of an intrauterine 
contraceptive device
5) Amoeba have been found in association with the presence of an IUD, as has 
Eubacterium nodatum which mimics actinomyces
Reparative or reactive changes
Reparative processes are often encountered
1) With estrogen deficiency
2) Surgery
3) Radio therapy
4) Intercourse
5) IUD users     
Epithelial cell abnormality
1) Atypical squamous cells
- as of undetermined significance (ASC-US)
- as suggestive of a high grade squamous intra epithelial lesion (ASC- H)
2) LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION (LSIL)
LSIL is most prevalent in women in their early reproductive years (16 to 26 
years) The cytological abnormal squamous cells that are equivalent in size to a normal 
superficial  or  intermediate  cell.  Diagnostic  abnormalities  include enlargement  of the 
nucleus, irregularity of the nuclear membrane and irregular chromatin distribution.
3) HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL)
HSIL is most prevalent in women in their mid to late reproductive years  (26 to 
48 years) The cytologic diagnosis of HSIL relies on the presence of abnormal squamous 
cells  that  are  smaller  than  those  seen  in  LSIL.  The  average  size  of  a  high  grade 
squamous  intraepithelial  lesion  is  equivalent  to  that  of  a  normal  parabasal  cells. 
Diagnostic abnormalities include nuclear enlargements, marked increase in nuclear to 
cytoplasmic  ratio,  irregularity  of  the  nuclear  membrane  and  irregular  chromatin 
distribution.
4) Glandular cells
Endometrial cells, Cytologically benign in postmenopausal women.
Atypical glandular cells of undetermined significance
Endo-cervical adenocarcinoma
PAP STAINING PROCEDURE
Papanicolaou  staining  technique  gives  a  dependable  nuclear  morphology  and 
cytoplasmic transparency.
The composition of the stain is
Harris Haematoxylin-stains the nuclei
OG 6 (orange G)-stains keratin if present
EA 50 (has Light green, Bismarck brown & eosin yellow)-stains
Superficial cells-pink; intermediate and parabasal cell cytoplasm-blue-green
CELL COMPONENTS IN A PAP SMEAR
Basal  cells  -  rarely  seen except  in  atrophic  vagina.  Small  round cells  with  smooth 
border and a central round nucleus
Parabasal  cells  - uniform round cells  with  a thick blue  or  green cytoplasm.  Large 
central round nucleus
Intermediate cells - polyhedral cells with thin semitransparent pink to blue cytoplasm 
and  central  large  vesicular  nucleus.  A  folding  or  curling  tendency  of  the  edges 
(navicular cells) is seen in pregnancy.
Superficial cells - most common and largest epithelial cells in a pap smear. Polyhedral 
cells with a thin homogenous cytoplasm pink to orange (if keratin is present). Nucleus is 
central and pyknotic.
Endocervical ciliated or nonciliated cells, endometrial cells can also be seen depending 
on the site of collection.
Pap smear and cancer screening.
Precursor changes in the uterine cervix are dysplasia and carcinoma in situ.  Invasive 
cervical cancer is a slow and predictable process.  Pap smear is a standard effective 
method of screening for malignant cells.
For an accurate interpretation of the smear the sample should be adequate.  Satisfactory 
smears should fulfill-patient and specimen identity, pertinent clinical details, technically 
good sample and proper cellular composition, cervical transformation Zone should be 
present.
The most common reason for an unsatisfactory sample is scant cellularity and 
obscuring inflammation and blood.
LIQUID BASED THIN LAYER CYTOLOGY
Liquid based, thin layer cytology was developed to overcome the limitations of 
the conventional Pap smear-failure to capture the entire sample, inadequate fixation, 
random distribution of abnormal cells, obscuring elements and technical variability of 
the quality of smear.
In conventional smear the transfer of cells onto a glass slide is a random event 
and is statistically prone to error.  Prompt fixation is to be done to prevent air drying. 
15% of Pap smears are limited owing to the presence of obscuring elements i.e., blood 
and inflammation.
In liquid based thin layer cytology the mechanical mixing of cells with the liquid 
medium creates a homogenous sample in which abnormal cells are evenly distributed. 
Thin layer cytology gives good quality smears which show crisp cell details, lack of 
smearing pattern and absence of obscuring elements like blood and debris.
AUTOMATION AND PAP SCREENING
Computer assisted screening has shown to reduce the number of false negative 
smear reports. A set of images of stained cervical epithelial cells is used to calculate the 
quantitative features and these features are used to detect abnormal or malignant cells.  
The various devices are Auto Pap 300 and papnet.  These are based on neutral 
network technology and present images with least normal appearance
In  India  a  system  called  Cytoscan  has  been  developed  by  the  defence 
bioengineering and electro medical laboratory. Cytoscan is a PC based interactive image 
analyzer. A binocular microscope with a Close Circuit Digital camera and a PC is the 
unit.  The pap smear images are acquired by the camera digitized by the frame grabber 
the PC and images seen on the screen.
Automation increases the sensitivity and specificity and reduces false negative 
reports  and  may  very  soon  become  an  inevitable  way  of  screening  Pap  smears. 
However  they  cannot  replace  the  work  of  cytotechnologists  or  pathologists. 
Pathologists will have to give their final opinion on abnormal smears.
COLPOSCOPY
The term colposcopy specifically refers to the cervix. It is broadly used to mean 
the magnified illumination of the entire lower of female genital system including the 
vulva, vagina and cervix.
Colposcopy was first described by Hinselman in 1920.
Colposcopy allows the examiner to identify  specific  colposcopic features that 
distinguish  normal from abnormal findings and to form an impression as to whether the 
features are benign or are the hall marks  of  preinvasive or  invasive disease.
COLPOSCOPE
The modern optical colposcope is a binocular microscope with a built in light 
source  and  a  converging  objective  lens  attached  to  a  support  appliance.  Most 
colposcopes have focal length at around 300 mm. Low power x 2 to x6 is typically used 
for examination of vulva.
Medium power x 8 x 15 is generally used for examination of the vulva, vagina and 
cervix.
High power x 15x 25 is used for assessing the fine detail of vessel patterns.
Normal Findings In Colposcopy
1.The squamous cervical epithelium appears smooth, pink & translucent.
2.Columnar epithelium appears more pink - red,
3.Squamo columnar junction is smooth or serrated.
4.Transformation Zone:
Transformation  Zone  is  defined  colposcopically  as  the  area  bordered  by  the 
original and the new squamo columnar junction. The location of the squamo columnar 
junction  is  variable.  During  reproductive  life,  the  squamo  columnar  junction  is 
commonly located near the external os or on the portio.
In this zone there is intermingling areas of columnar and metaplastic squamous 
epithelium. The transformation zone area is altered by exposures to oral contraceptive 
medications. pregnancy, pH changes in the vagina and vaginal infections. It is difficult 
to  differentiate  colposcopically  where  metaplasia  ends  and  the  mature  squamous 
epithelium of the ectocervix begins.
5. Vascular Changes 
Vascular changes can be seen in areas of metaplasia.  The vessels are usually 
hairpin in shapes and 50 to 250  µm apart. Capillary loops extending to the epithelial 
surface are seen as punctate dots. Because the vessels that  proliferate within squamous 
metaplasia are small, punctation is fine and the intercapillary distances between the dots 
is close.
Atypical Transformation Zone 
Transformation Zone is called atypical when the following features are present in 
both benign and in pre invasive lesion.
1. Leucoplakia
2. Acetowhite epithelium 
3. Punctation - The vessels all often spaced at greater distance from one another 
compared with capillaries of native squamous epithelium. Distance between the 
capillaries increases progressively in dysplasia, carcinoma in situ and invasive 
carcinoma.
4. Mosaic- the pathological vessels form a basket like structure around block of 
pathological epithelium.
5. Atypical vessels 32
COLPOSCOPIC ABNORMALITY-RUBIN AND BARBO 
COLPOSCOPIC ASSESMENT SYSTEM 32 
Grade Colour Vessels Border Surface
Normal PinkTranslucent
Fine, lacy,
Normal 
branching
Normal
Transformation 
zone.
Flat
Grade 1
Mild dysplasia 
CIN 1
LSIL
White
Shiny white
Snow white
None
Fine punctation 
Mosaic 
Diffuse
Feathery
Flocculated
Geographic
Flat
Micropapillary
macropapillary
Grade 2 
Moderate 
dysplasia 
CIN 2
HSIL
Whiter
Shiny grey
White
None
Punctation
mosaic
Clearly
Demarcated 
Flat
Slightly raised
Grade 3
Severe 
dysplasia 
CIN 3
HSIL
Whitest
Dull white
Oyster white
None
Coarse 
punctation
Coarse mosaic 
Dilated 
increased 
Inter capillary
distance
Sharp
Demarcated 
Straight
Internal border
Raised
Micro 
invasion
Frank invasion
Red
Yellow
Dull grey
Atypical
Irregular
Bizarre 
Clearly 
demarcated
Peeling 
Rolled
Edges
Nodular
Ulcerated
Necrotic
Exophytic 
Miscellaneous Findings
Condylomatous lesions
Inflammation
Atrophy
Ulcer
Endometriosis
Others
Ectopy
Columnar epithelium situated on the ectocervix some distance from the external 
os is called ectopy. The columnar epithelium of the endocervical canal is everted onto 
the outer aspect of the cervix. The squamo columnar junction is on the outer aspect of 
the cervix, not in the endocervical canal.
Ectopy  appears  classically  as  a  red  patch.  Ectopy  is  formed  by  columnar 
epithelium, which does not contain glycogen, it is always iodine negative. Ectopy is 
usually covered by mucus secreted by the columnar epithelium. Dilute acetic acid 3% 
helps to remove the mucus, revealing a distinctive papillary structure and causes the 
tissue  to  swell.  This  throws  the  mucosal  architecture  into  sharp  rete  and  gives  the 
papillae a grape like appearance. After the application of diluted acetic acid the intense 
red of  the  red patch of  ectopy changes  to  a pink or  whitish colour.  The Squamous 
Columnar  Junction  (SCJ)  is  the  border  between  the  squamous  epithelium  on  the 
ectocervix and the columnar epithelium of the endocervical canal. Normally it lies on 
the ectocervix and is sharp and steplike. But careful examination of the margin at the 
SCJ often reveals a slender seam, a white colour, and gland openings indicating, the 
initiation of the transformation of columnar epithelium to squamous epithelium. This 
process of transformation is called metaplasia. It is important to pay close attention to 
the margins of ectopy so that significant lesions are not over looked.
The  process  of  transformation  characteristically  begins  at  the  SCJ.  It  is 
impossible to tell Colposcopically whether transformation process at this site is due to 
ascending healing or to squamous metaplasia. Fields of metaplastic epithelium within a 
transformation zone can vary widely in their maturation and are easily verifiable with 
Schillers test. The topographic progress of transformation may be haphazard. Islands of 
squamous epithelium can appears  in  a  sea  of  columnar epithelium.  The metaplastic 
epithelium can form finger like process that interdigitate with columnar epithelium. The 
transformation  of  an  ectopy  may  not  always  proceed  to  completion,  and  areas  of 
columnar epithelium can remain in the native state.  The transformation zone can be 
distinguished from original epithelium only by the presence of gland openings, more 
prominent vessels and Nabothian cysts.
Colpitis
Colpitis is the diffuse erythema of the cervix and vagina that is the result of an 
infection  such  as  trichomoniasis  or  candida  species.  Underlying  stromal  vessels  are 
dilated and the  tips are visible through the overlying denuded squamous epithelium, 
appearing as fine red dots. This is distinguished from punctation in which the red dots 
are  found within  a  field  of  aceto  white  epithelium.  After  the  application  of  Lugols 
solution,  the  denuded,  inflamed  epithelium  exhibits  poor  iodine  uptake,  produce  a 
“Leopard-skin” or Pepper spot appearance, blotchy pattern.
Unsatisfactory Colposcopy
An unsatisfactory colposcopic examination means that the examiner cannot see 
all or part of the squamous columnar transformation zone.
If the colposcopy is unsatisfactory and cannot be relied upon, other means to 
make diagnosis must be embarked upon.
Obviously the colposcopic examination was indicated in the first place because 
of cytologic abnormalities or other stated reason. Repeated cytological samples is not an 
appropriate methodology to obtain the diagnostic goal. If the cervical canal is stenotic or 
if the transformation zone lies in the endocervical canal, a small cone performed by 
knife,  laser  or  electrical  loop  will  confirm  or  refute  the  diagnosis  of  cervical 
intraepithelial neoplasia.

COLPOSCOPY - PICTURES
LSIL

SUBJECTS AND METHODS
           
This  was  a  prospective  study conducted  at  Govt.  Kasturbha  Gandhi  hospital, 
Chennai at the department of obstetrics and gynecology from November 2003 to March 
2006.
This study comprised of study subject [n=298] using intrauterine contraceptive 
device for more than 6 months and attended family planning clinic for follow up.
                         
INCLUSION CRITERIA:
1.Subjects using intrauterine contraceptive device for more than 6 months.
2.The subjects were chosen irrespective of their socio-demographic profile.
3.Never on any other contraceptive method.
4.In active sexual life.
EXCLUSION CRITERIA:
1.Subjects with IUD  using less than 6 months.
2.Subject with missing IUD
3.Subjects with pregnancy with IUD in situ.
METHODS:
The subjects were explained about the study and consent was obtained. Detailed 
history including any complaints, menstrual history, obstetric history and duration of 
IUD use was obtained. Each subject underwent general physical, systemic, abdominal 
examination. Then the acceptors was subjected to colposcopic examination. 
Colposcopic Examination technique: 
               
1. The supplies and equipment are checked before the examination is begun.
2. The  proper  documentation  forms  stamped  with  the  patient  identification  is 
obtained.
3. The patient is placed in the dorsal lithotomy position and properly draped.
4. The colposcopist sits comfortably at the colposcope, the interpupillary distance 
of the binoculars is set and the colposcope is tuned on.
5. The vulva is inspected with the colposcope.
6. The largest size of intravaginal speculum that the patient can tolerate is placed in 
the vagina.
7. The cervix must be adequately visualized and look for thread of IUD and any 
discharge. Pap smear for cytological study is taken. The Ayre’s spatula is first 
placed at the external os. It is rotated 360 degrees around the circumference of 
os,  maintaining  contact  with   the  ectocervix.  The  endocervical  brush  is  then 
inserted into the os and rotated to 180 degrees maintaining contact  with the 
cervical canal. Both ectocervix and endocervix samples are smeared on the glass 
slide and immediately fixed in alcohol fixative for 30 minutes. The slide is then 
labelled.
8. The cervix is viewed with white light under low power. Gross findings and the 
presence of leucoplakia are noted.
9. The vessel pattern is examined with the green filter. The vessels are examined 
under low and high magnification.
10. A copious amount of 5% acetic acid is applied to the cervix with saturated cotton 
swabs.Excessive rubbing of the cervix was avoided.
11. The cervix is assessed for epithelial patterns after the acetic acid application with 
low , intermediate and high magnification.
12. The cervix is stained with Lugols iodine solution. An assessment of the epithelial 
patterns is dependent on the interaction between cellular glycogen and iodine.
13. The vagina is inspected as the speculum is removed.
14. The documentation form is completed. The colposcopic findings is mentioned as 
satisfactory or unsatisfactory, normal or abnormal.32
                     
The pap smear after fixing is transported to the pathology laboratory, where it is 
stained and read by cytologist. The cytological abnormality is reported as per Bethesda 
system. 32
The clinician, colposcopist and pathologist were unaware of the group of patients.
The women were reviewed a week later using the gathered information. The patients 
were managed as per the findings. Subsequent treatment was individualized depending 
upon the diagnosis and patient’s convenience.
All  the  clinical  ,  colposcopic  and  cytological  findings  were  recorded  in  a 
predesigned proforma.  The  datas  were  analysed  with the  help  of  a  statistician.  The 
results were expressed as percentages and mean. The statistical analysis is done by chi-
square test and anova-inferential statistics.    
                              
RESULTS
As  previously  discussed  the  study  population  included  298 subjects  using 
intrauterine contraceptive device for variable period from more than 6 months to 4 years 
attending the family planning OPD Govt Kasturbha Gandhi Hospitals, Chennai. All the 
298 subjects were using either Cu –T 200 or Cu-T 380A.
Table I
Gives the age distribution of the study
Age Number of Subjects Percentage (%)
Below 20 10 3.4
20-24 155 52
25-29 84 28.2
30-34 32 10.7
35-39 15 5
40 & above 2 0.7
52% of  the  subject  were  between 20-24 years  of  age  and  only  3.4% of  the 
subjects were below 20 years and 0.7% of the subjects were above 40 years. Mean age 
of the study group was 24.8 years.
Table 2
Age at Marriage
Age at 
Marriage
Number of 
Subjects Percentage (%)
17-19 97 32.6
20-22 167 56
23-25 31 10.4
26-28 3 1
88.6% of the subjects had their marriage before 23 years and only 1% of the 
subjects  had their marriage after 26 years of age. About 32.6% of the subjects  had their 
marriage in the teen age due to the prevailing social custom of a particular group of 
people.
Table 3
Parity
Number of 
Children
Number of 
Subjects Percentage (%)
1 225 75.8
2 60 20.2
3 12 4
About 75.8% of the subjects had one child and only 4% of the subjects  had 3 children
Table 4
Duration of Intrauterine
Contraceptive device use in Months
Duration in 
months
Number of 
Subjects Percentage (%)
Below 1 year 39 13.08
1 year to 
below 2 years 173 58.05
2 years 61 20
Above 2 
Years 25 8.3
The duration of IUD use varied between 7 months to 4 years. 78% of the subjects 
used IUD for 1 to 2 years. Only 8.3% of the subjects used IUD above 2 years
Table 5
Colposcopic Changes
Colposcopic Findings
Number of 
Subjects
Percentage (%)
Normal Study 216 72.5
Colpitis 59 19.8
Ectopy 18 60
Low Grade Squamous 
Intraepithelial lesion (LSIL)
4 1.3
High grade Squamous 
Intraepithelial lesion (HSIL)
1 0.3
Table 6
COLPOSCOPIC CHANGES
COLPOSCOPIC
CHANGES
AGE AGE AT 
MARRIAGE
DURATION OF 
IUD USE IN 
MONTHS
Normal study
N=216
Mean
Std deviation
23.8
3.664
20.07
1.776
15.73
7.324
Colpitis
N=59 is 
Mean
S-D
26.12
4.056
20.66
1.516
21.02
8.617
Ectopy
N=18
Mean
SD
30.06
4.45
21.89
2.72
24.33
7.554
LSIL 
N=4
Mean
SD
38.50
2.646
18.50
0.5
31.50
5.745
HSIL
N=1
Mean 36.00 2.00 18
NORMAL STUDY
72.5% of the subjects had normal colposcopic features and the mean age of the 
subjects was 23.8 years.  The mean duration of IUD use was 15.73 months. 81.9% of 
the subjects  were primi para
COLPITIS 
19.8% of the subjects had colpitis. The mean age of the subjects was 26.12 years. 
The mean duration of IUD use was 15.73 months.
ECTOPY:
6.0% of the subjects had ectopy. The mean age of the subject was 30.06 Years. 
Mean duration of IUD use was 24.33 months.
Table 7
Cytology
Cytology
Number of 
Subjects
Percentage (%)
Normal Study 65 21.8
Inflammatory 
Changes
228 76.5
LSIL 5 1.7
TABLE 8
CYTOLOGICAL CHANGES
Cytology Age Marriage Duration  of 
IUD  use  in 
Months
Normal 
Study
Means 
SD
22.82
3.67
19.51
1.79
14.12
7.347
Inflammatory 
Changes
Mean
SD
25.17
4.116
20.53
1.809
18.23
8.058
Dysplastic 
change LSIL
Mean
 SD
38
2.5
18
0.8
28.80
7.823
NORMAL
The mean age of the subjects in the study was 22.8 years, and the mean duration 
of IUD use in months was 14.12, mean age at marriage was 19.5 years, 89.2% of the 
subjects were primipara.
INFLAMMATORY CHANGES
The mean age of the subject was 25.17 years, and mean duration of IUD  use was 18.23 
months.
LOW GRADE SQUAMOUS INTRA EPITHELIAL LESIONS (LSIL)
Only 5 subjects had LSIL in cytology, of this 4 subjects had LSIL and 1 subject 
had HSIL in colposcopy.  
Colposcopically directed biopsy was done for these 5 subjects. 4 subjects with 
LSIL  had chronic non specific cervicitis in histopathology. 1 subject with HSIL showed 
severe dysplasia in histopathology and this subject with severe dysplasia was 36 years 
old and has 3 children and she was not willing for conservative line of management  ;so 
total hysterectomy was done. Other 4 subjects with Chronic non specific cervicitis are 
followed with papsmear regularly once in 6 months.
Colposcopic and Cytological Changes with relation to Duration of IUD’ use
Table 9
COLPOSCOPIC CHANGES
Duration of IUD use in 
Months Observed N
Below 1 Year 
n=39
Normal Study 37
Infection 2
1 to Below 2 Years
n=173
Normal Study 137
Infection 30
Ectopy 5
High grade SIL 1
2 and above Years
n=86
Normal Study 42
Infection 27
Ectopy 13
Low grade SIL 4
Table 10
CYTOLOGY
Duration of IUD use in 
Months Observed N
Below 1 Year
N=39
Normal Study 22
Inflammatory 
Changes 17
1 to Below 2 Years
n=173
Normal Study 32
Inflammatory 
Changes 140
 LSIL 1
2 and above Years
n=86
Normal Study 11
Inflammatory 
Changes 71
 LSIL 4
By applying chi square test it was found that with increase in duration of IUD, 
there  is  statically  significant increase (p less  than 0.01)  in  inflammatory  changes  in 
cytology  &  colposcopy,  But  only  1.7%  of  the  subjects  had  low  grade  squamous 
intraepithelial lesion, which is same as the incidence in general population[1.6%], and 
due to very less subjects with LSIL their association with duration of IUD use cannot be 
established.

Duration of IUD use in Months
Duration of IUD use in Months
--CYTOLOGY
COLPOSCOPIC CHANGES
 
DISCUSSION
In this study 298 subjects using intrauterine contraceptive device between 6 months to 4 
years  were  studied.  They  were  examined  colposcopically  and  cytologically  for 
associated cervical pathological lesions.
AGE:
The mean age of IUD users was 26.4 years
AGE AT MARRIAGE
The mean age at marriage of the subjects was 20 .8 years.
PARITY
75% of the subjects had one child 
DURATION OF IUD USE
The mean duration of IUD use was 17.5 months. 
Agarwal Krishna – etal. In their study of microbiological and cytopathological study of 
intrauterine, device users, studied a total of 100 IUD users and 50 matched controls. The 
mean duration of IUD use in their study was 2 years.
COLPOSCOPIC CHANGES
About 216 subjects i.e., 72.5 % had normal Colposcopic changes.
About 19.8% had colpitis which appeared as pepper spot appearance which is 
suggestive of trichomonas vaginalis infection. Microbiological confirmation was done 
by wet film preparation.
Fiore-N in study of epidemiological data, cytology and colposcopy in IUD users, 
Estroprogestones and diaphragn users found that there is high frequency of trichomonas 
vaginalis infection in IUD users.
Ectopy
Ectopy of cervix is found in 6% of IUD users .The thread of IUD tail being source of 
constant irritation and may be responsible for cervical erosion (Agarwal Krishna et al)
Agarwal Krishna et al in the study of micro biological and cytopathological study in 
IUD users, 100 intra uterine device users were compared with 50 controls, found that 
cervical erosion is found in 20% among IUD users. Versus none in controls. Though 
cervical  erosion in  not  considered something with severe  implication  but  it  may be 
responsible for white discharge in IUD users, .
Nayar et al in their study of incidence of actinomyces infection in women using IUD 
reported 13% of cervical erosion among IUD users
CYTOLOGY
21.8% of the subjects had normal cytology
INFLAMMATORY CHANGES
76.5% of the IUD users in the present study had inflammatory changes in the 
cytology. Ismail H, el Tewil A, Fahmy k,  in their study of cervical pathology with IUD 
– a cyto – colpo-pathological study. They studied 100 Lippes loop users and 100 Cu-T –
200 users for >1 year and 200 control  non users by cytology, colposcopy and histo 
pathology  for  associated cervical  pathology.  They found significant  increase  in  non 
specific inflammatory changes (P less than 0.05).in the IUD users than the non users.
Ashwani etal reported an incidence of inflammatory changes of 57% at 6 wks, 72.6% at 
6 months of Cu-T insertion. 
Agarwal  Krishna et  al  in  their  study of  microbiological  and  cytopathological 
study of intra uterine device users found that there is slightly increased incidence of 
inflammatory smear in the IUD users compared to non users.
DYSPLASTIC CHANGES
Only  5  cases  i.e.,  1.7%  of  cases  had  low-grade  squamous  intraepithelial 
neoplasm, by cytology. Out of the 5 cases  4 cases had LSIL by colposcopy and 1 case 
had HSIL by colposcopy. For this 5 cases colposcopically directed cervical biopsy was 
done. Only the HSIL lesion was found have severe dysplasia in histopathology. Other 4 
cases was found to be chronic non specific cervicitis in histopathology. The incidence of 
dysplasia  in  the  study  group  is  comparable  to  the  incidence  of  general  population 
general population which is 1.6%. 
Famhy K etal in their study of cervico pathology in IUD users – a cyto – colpo – 
pathological study  reported there was  statistically no significant difference(p >0.05) in 
the incidence of dyskaryosis or CIN between both groups by cytology and colposcopy. 
Medbat etal in their case control study under took to investigate the effects of 
IUD on the histology of cervical epithelium. 91 women who had used IUDs for 2–13 
years  where  case  subjects  and  were  compared  with  the  same  number  of  non 
users.2subgroups were investigated group A and group B .Group A consisted of 53 IUD 
users  and  53  controls  coming  to  family  planning  and  gynaecolgy  clinics.Group  B 
consisted of  38 cases of IUD users and 38 controls from dysplasia clinics. Cervical 
cytology and  colposcopically directed biopsy were taken in all women. There was no 
differnce between IUD users and control subjects in the proportion or the severity of 
dysplasia in either Group A or Group B. . There was no evidence of an increase in the 
prevalence or severity of dysplasia with prolonged IUD use.
Agarwal Krishna etal their study found that the incidence of dysplastic changes 
in IUD users is comparable with general population. 
The present study showed incidence of inflammatory smear as 43% at 1 year of 
use, 80% at 2 years of IUD insertion.
Ashwani etal reported an incidence of inflammatory smear as 57% at 6 weeks, 
72.6% at 6 month of Cu-T insertion.
There is significant increase in non specific inflammatory changes in cytology in 
IUD users.  No  significant  increase  in  the  dysplastic  changes  in  IUD users  in  both 
colposcopy and cytology.
SUMMARY
1. In this study the mean duration of IUD use is 17.5 months
2. 76 % of the study subjects had inflammatory changes in cytology 
3. The incidence of inflammatory change is associated with the duration of the intra 
uterine contraceptive device use.
4. There  is  no  significant  increase  in  incidence  of  low  grade  intraepithelial 
neoplasia and high grade intraepithelial neoplasia in IUD users.
CONCLUSION
The  present  study  indicates  that  there  is  a  definite  change  in  the  cervical 
architecture in IUD users and the change is also dependent on the duration of use. A 
simple  technique  like  colposcope  is  highly  useful  in  diagnosing  these  changes  and 
combating them by early interference wherever necessary. However the present study 
and some of the earlier studies does not reveal any increased risk of dysplasia in IUD 
users over their non using sisters. However the need for regular and periodical follow up 
cannot be over emphasized particularly those who wish to use the IUD as a long term 
contraception.
PROFORMA
Name Age O.P .NO
Occupation
Socio economic status
Address
Duration of IUD use 
Type of IUD use
Complaints
History of present illness
Mode of onset
Duration
Course
Symptoms
Menstrual history
Duration of flow
Length of cycle
Amount of flow
Associated Pain
Last menstrual period
Marital History
Age at marriage
Living with the husband or not 
Any high risk behaviour of both the partners
Obstetric History
Number of children Alive
Type of delivery
Last child birth
General examination
Built 
Aneamia
Lymphadenopathy
Abdominal examination
Any distension or mass
Any tenderness
Speculum examination
Position of thread of IUD
Status of cervix
Colposcopic examination and cytological examination
Bimanual pelvic examination
Position of cervix
Size of uterus
Position of uterus
Mobility
Consistency
Fornices
Colposcopic findings
Satisfactory or unsatisfactory 
Type of study
If abnormal –site of lesion 
If there is features suggestive of  colpitis, wet film preparation for trichomonas vaginalis
Cytological findings
If  there  is  LSIL or HSIL  by colposcopy and cytology then colposcopically directed 
ectocervix   biopsy is taken and specimen sent for histopathology.
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MASTER CHART
S.No Name Age Age At 
Marriage
Number of 
Children
Duration of 
Cu T use in 
Months
COLPOSCOPIC 
CHANGES
CYTOLOGY Socio 
Economic 
Status
1 VANAJA 30 27 1 24 Normal Study Normal Study 4
2 SHAKILA 25 19 1 36 Colpitis Inflammatory 
changes
5
3 PARVEEN 23 18 2 24 Normal Study Inflammatory 
changes
5
4 JEYANTHI 25 20 1 12 Normal Study Inflammatory 
changes
5
5 SATHYA 23 20 1 12 Normal Study Inflammatory 
changes
5
6 MARI 20 18 1 18 Normal Study Normal Study 5
7 RENUKA 22 19 1 24 Colpitis Inflammatory 
changes
5
8 KANIMOZHI 19 18 -- 8 Normal Study Inflammatory 
changes
5
9 VIJAYALAKSHMI 26 23 1 8 Normal Study Inflammatory 
changes
5
10 BINDHU 30 23 1 24 Normal Study Inflammatory 
changes
5
11 SABEENA 21 19 1 8 Normal Study Normal Study 3
12 UMAMAHESHWARI 21 17 1 12 Ectopy Inflammatory 
changes
4
13 NAVANEETHAM 24 19 2 18 Normal Study Inflammatory 
changes
4
14 NARMADHA 20 18 1 12 Normal Study Normal Study 4
15 KALAIARASI 25 20 2 18 Normal Study Normal Study 4
16 VIMALA 29 22 2 12 Normal Study Inflammatory 
changes
5
17 SAMAYAPURAM 30 19 3 24 Normal Study Inflammatory 
changes
5
18 DEEPA 25 23 1 12 Normal Study Inflammatory 
changes
5
19 YUVARANI 21 18 1 18 Normal Study Inflammatory 
changes
5
20 USHA 24 20 1 36 Ectopy Inflammatory 
changes
3
21 CHANDRA 22 19 1 24 Normal Study Inflammatory 
changes
3
22 KALAISELVI 22 20 1 12 Colpitis Inflammatory 
changes
3
23 SELVI 29 21 1 36 Colpitis Inflammatory 
changes
4
24 SUDHA 25 21 1 18 Normal Study Normal Study 4
25 LAKSHMI 21 18 1 18 Normal Study Inflammatory 
changes
4
26 MUTHAMMA 35 18 3 36 LSIL LSIL 3
27 JEYANTHI 32 25 2 12 Normal Study Inflammatory 
changes
3
28 SARASWATHI 30 20 2 24 Normal Study Inflammatory 
changes
4
29 DHARANIDEVI 22 20 1 12 Normal Study Inflammatory 
changes
4
30 SABEENA 38 19 3 30 LSIL LSIL 4
31 ALAMELU 35 25 3 24 Ectopy Inflammatory 
changes
4
32 LAKSHMI 23 20 1 24 Normal Study Inflammatory 
changes
5
S.No Name Age Age At 
Marriage
Number of 
Children
Duration of 
Cu T use in 
Months
COLPOSCOPIC 
CHANGES
CYTOLOGY Socio 
Economic 
Status
33 SANDHIYA 25 23 1 12 Colpitis Inflammatory 
changes
5
34 RANI 27 19 1 24 Colpitis Inflammatory 
changes
5
35 SREEMATHI 36 20 2 24 Normal Study Normal Study 5
36 SELVI 37 20 2 42 Normal Study Inflammatory 
changes
3
37 SARALA 27 23 1 24 Normal Study Normal Study 3
38 FATHIMA 21 19 1 12 Normal Study Normal Study 4
39 KASTHURI 32 23 2 24 Colpitis Inflammatory 
changes
4
40 MAHALAKSHMI 32 22 2 36 Normal Study Inflammatory 
changes
4
41 ANANDHI 22 20 1 24 Normal Study Inflammatory 
changes
4
42 SARASU 25 22 1 12 Colpitis Inflammatory 
changes
4
43 MURKAAN 21 19 1 12 Normal Study Normal Study 5
44 RESHMA 20 18 1 24 Normal Study Normal Study 5
45 MALLIGA 25 22 1 48 Colpitis Inflammatory 
changes
5
46 MALA 30 20 2 48 Normal Study Inflammatory 
changes
5
47 NITHAYALAKSHMI 20 18 1 24 Normal Study Inflammatory 
changes
5
48 SARALA 33 22 2 36 Normal Study Inflammatory 
changes
4
49 ABRAMI 25 20 1 24 Normal Study Normal Study 4
50 SYED ALI FATHIMA 20 18 1 12 Normal Study Normal Study 4
51 LALITHA 24 20 1 18 Colpitis Inflammatory 
changes
4
52 CHANDRA 25 22 1 24 Normal Study Inflammatory 
changes
5
53 GEETHA 21 19 1 12 Normal Study Normal Study 5
54 GAYATHRI 24 22 1 12 Normal Study Inflammatory 
changes
5
55 SELVI 25 20 2 18 Normal Study Inflammatory 
changes
4
56 AMMLU 26 23 1 24 Ectopy Inflammatory 
changes
5
57 SARANYA 23 20 1 12 Normal Study Normal Study 4
58 AMUDHA 24 22 1 12 Normal Study Normal Study 5
59 GOMATHY 23 20 1 24 Normal Study Inflammatory 
changes
4
60 PARVATHY 23 20 1 18 Normal Study Normal Study 5
61 KAVITHA 23 21 1 12 Normal Study Normal Study 4
62 RUBA 40 18 3 36 LSIL LSIL 5
63 CHITRA 27 23 1 48 Normal Study Normal Study 4
64 RANI 36 24 2 36 Colpitis Inflammatory 
changes
5
65 SHAMEEM 21 19 1 12 Normal Study Inflammatory 
changes
4
66 SIVAGAMI 30 24 2 24 Normal Study Inflammatory 
changes
5
67 PARVEEN 24 20 1 24 Normal Study Normal Study 5
68 KALPANA 28 22 1 36 Normal Study Normal Study 5
69 VARALAKHSMI 24 20 1 18 Colpitis Inflammatory 
changes
5
70 SUNDARI 23 20 1 18 Normal Study Normal Study 5
S.No Name Age Age At 
Marriage
Number of 
Children
Duration of 
Cu T use in 
Months
COLPOSCOPIC 
CHANGES
CYTOLOGY Socio 
Economic 
Status
71 VASANTHI 21 19 1 12 Normal Study Inflammatory 
changes
3
72 PRIYA 20 18 1 12 Colpitis Inflammatory 
changes
4
73 RESHMA 22 19 1 24 Normal Study Inflammatory 
changes
5
74 MANJULA 30 20 2 18 Ectopy Inflammatory 
changes
3
75 UMARANI 20 18 1 12 Normal Study Inflammatory 
changes
4
76 MARIYA 27 20 2 18 Colpitis Inflammatory 
changes
5
77 DEVI 21 19 1 12 Normal Study Inflammatory 
changes
5
78 SUDHA 27 20 2 24 Normal Study Normal Study 5
79 SATHYA 23 19 1 18 Normal Study Inflammatory 
changes
5
80 SHALINI 31 21 2 36 Ectopy Inflammatory 
changes
5
81 LAKSHMI 38 20 3 24 Normal Study Inflammatory 
changes
3
82 GEETHA 25 20 1 36 Colpitis Inflammatory 
changes
3
83 RANI 33 20 2 48 Normal Study Inflammatory 
changes
4
84 CHITRALEKHA 25 21 1 18 Normal Study Inflammatory 
changes
5
85 SUMATHI 22 20 1 12 Normal Study Normal Study 4
86 MUKTHIYAR BEGUM 19 17 1 8 Normal Study Normal Study 5
87 MALATHI 23 20 1 12 Colpitis Inflammatory 
changes
4
88 GEETHA 22 20 1 12 Normal Study Inflammatory 
changes
5
89 FATHIMA 24 21 1 24 Colpitis Inflammatory 
changes
4
90 DEVI 21 19 1 12 Normal Study Normal Study 5
91 SANGEETHA 23 20 1 24 Normal Study Inflammatory 
changes
4
92 DEVI 25 22 1 18 Normal Study Inflammatory 
changes
5
93 MARI 20 18 1 18 Normal Study Inflammatory 
changes
4
94 LAKHSMI 23 20 1 24 Colpitis Normal Study 5
95 PATHMALATHA 25 22 1 18 Normal Study Inflammatory 
changes
4
96 SATYA 23 20 1 12 Normal Study Inflammatory 
changes
4
97 SREEMATHI 26 20 2 12 Colpitis Inflammatory 
changes
4
98 KALAIVANI 23 20 1 12 Normal Study Normal Study 5
99 SASIKALA 23 19 1 18 Normal Study Inflammatory 
changes
5
100 DHARANI 32 20 2 24 Colpitis Inflammatory 
changes
5
101 SIKANDAR 22 20 1 12 Normal Study Inflammatory 
changes
4
102 UMARANI 20 18 1 12 Normal Study Inflammatory 
changes
4
S.No Name Age Age At 
Marriage
Number of 
Children
Duration of 
Cu T use in 
Months
COLPOSCOPIC 
CHANGES
CYTOLOGY Socio 
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Status
103 SUMATHI 21 19 1 18 Normal Study Inflammatory 
changes
4
104 JHANSI RANI 26 22 1 24 Normal Study Inflammatory 
changes
4
105 JEYASUDHA 35 25 2 36 Ectopy Inflammatory 
changes
5
106 JASMINE 20 18 1 10 Normal Study Normal Study 5
107 DHANALAKSHMI 28 20 2 24 Colpitis Inflammatory 
changes
5
108 HAJEERA 25 22 1 12 Normal Study Inflammatory 
changes
5
109 VASANTHI 23 20 1 18 Normal Study Inflammatory 
changes
4
110 NARMADHA 28 21 2 24 Colpitis Inflammatory 
changes
4
111 JAYALAKSHMI 22 20 1 12 Normal Study Inflammatory 
changes
4
112 SUJATHA 28 24 1 18 Normal Study Inflammatory 
changes
5
113 NIRMALA 26 23 1 18 Ectopy Inflammatory 
changes
5
114 YASODHA 27 20 2 12 Normal Study Normal Study 5
115 SHOBANA 23 20 1 8 Normal Study Normal Study 5
116 RAJALAKHMI 26 23 1 12 Colpitis Inflammatory 
changes
3
117 RAHEMA BEE 19 17 1 8 Normal Study Normal Study 3
118 SARESWATHI 25 22 1 18 Normal Study Inflammatory 
changes
4
119 GANDHIMATHI 22 20 1 12 Normal Study Normal Study 5
120 LALITHA 32 22 2 36 Colpitis Inflammatory 
changes
4
121 YAMUNA 25 20 1 24 Normal Study Inflammatory 
changes
5
122 PRIYA 30 20 2 12 Normal Study Inflammatory 
changes
4
123 BHARATHI 23 20 1 18 Normal Study Inflammatory 
changes
5
124 SYED ALIFATHIMA 22 19 1 12 Normal Study Normal Study 5
125 DEVIKA 20 18 1 8 Normal Study Normal Study 5
126 JEYALAKSHMI 35 20 3 24 Ectopy Inflammatory 
changes
5
127 SHOBA 21 19 1 12 Normal Study Inflammatory 
changes
3
128 SHABANA 20 18 1 8 Normal Study Normal Study 3
129 SAKILA 24 21 1 18 Normal Study Inflammatory 
changes
4
130 ARULMOZHIL 19 17 1 8 Normal Study Normal Study 4
131 SELVI 21 19 1 12 Normal Study Inflammatory 
changes
5
132 MAHESWARI 26 22 1 36 Colpitis Inflammatory 
changes
4
133 VARALAKSHMI 24 21 1 24 Normal Study Inflammatory 
changes
5
134 MANISHA 19 17 1 7 Normal Study Inflammatory 
changes
5
135 JAYANTHI 24 20 1 18 Normal Study Inflammatory 
changes
5
136 AMULU 30 20 2 24 Colpitis Inflammatory 
changes
5
S.No Name Age Age At 
Marriage
Number of 
Children
Duration of 
Cu T use in 
Months
COLPOSCOPIC 
CHANGES
CYTOLOGY Socio 
Economic 
Status
137 MAHESWARI 25 21 1 24 Normal Study Inflammatory 
changes
4
138 SHANTHI 32 20 2 24 Ectopy Inflammatory 
changes
4
139 SIVAKAMI 19 17 1 8 Normal Study Normal Study 4
140 SARASWATHI 25 22 1 12 Normal Study Inflammatory 
changes
5
141 AYESHA BEGAM 22 20 1 12 Normal Study Inflammatory 
changes
5
142 NIRMALA 23 19 1 24 Colpitis Inflammatory 
changes
5
143 SHANTHI 32 28 1 18 Normal Study Inflammatory 
changes
5
144 KANNAGI 25 22 1 18 Normal Study Inflammatory 
changes
5
145 SASIKALA 28 20 2 12 Normal Study Inflammatory 
changes
4
146 MAHESWARI 27 23 1 24 Ectopy Inflammatory 
changes
4
147 DEEPA 24 22 1 12 Normal Study Inflammatory 
changes
4
148 RENUGA 20 18 1 12 Normal Study Inflammatory 
changes
4
149 LATHA 20 18 1 8 Normal Study Normal Study 4
150 JEYALAKSHMI 31 20 2 18 Normal Study Inflammatory 
changes
3
151 SASIKALA 23 20 1 12 Normal Study Inflammatory 
changes
3
152 SANTHAKUMARI 22 20 1 12 Normal Study Inflammatory 
changes
4
153 MALLIGA 25 2 1 8 Normal Study Normal Study 5
154 DEVAKI 26 22 1 24 Colpitis Inflammatory 
changes
4
155 SAVITHA 22 20 1 12 Normal Study Inflammatory 
changes
5
156 DHANALAKSHMI 20 18 1 8 Normal Study Normal Study 4
157 RENUKA 24 20 1 36 Normal Study Inflammatory 
changes
4
158 SARASWATHI 24 22 1 12 Normal Study Inflammatory 
changes
5
159 KANMANI 24 20 1 18 Normal Study Inflammatory 
changes
4
160 BHAVANI 22 20 1 12 Normal Study Inflammatory 
changes
5
161 VIJAYALAKSHMI 20 18 1 8 Normal Study Inflammatory 
changes
4
162 KAVITHA 21 19 1 10 Normal Study Normal Study 5
163 EPSI 30 24 1 36 Normal Study Inflammatory 
changes
4
164 VAHINI 26 22 1 24 Normal Study Inflammatory 
changes
4
165 MURUGAMMAL 22 20 1 12 Normal Study Inflammatory 
changes
3
166 VARALAKSHMI 32 20 2 24 Ectopy Inflammatory 
changes
3
167 UMA 25 22 1 18 Normal Study Inflammatory 
changes
4
168 RAMYAEE 21 19 1 12 Normal Study Inflammatory 
changes
5
S.No Name Age Age At 
Marriage
Number of 
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Duration of 
Cu T use in 
Months
COLPOSCOPIC 
CHANGES
CYTOLOGY Socio 
Economic 
Status
169 FATHIMA 32 22 2 24 Colpitis Inflammatory 
changes
4
170 MEENAKSHI 24 22 1 12 Normal Study Inflammatory 
changes
4
171 SASIREKHA 20 18 1 8 Normal Study Normal Study 5
172 SAPNA 23 20 1 12 Normal Study Inflammatory 
changes
5
173 PUSHPARANI 22 20 1 10 Normal Study Normal Study 4
174 LAKSHMI 24 22 1 12 Normal Study Inflammatory 
changes
5
175 AYESHA 23 21 1 18 Normal Study Inflammatory 
changes
4
176 NITHYALAKSHMI 19 17 1 8 Normal Study Normal Study 5
177 SUDHA 20 18 1 8 Normal Study Inflammatory 
changes
5
178 KASTHURI 36 20 3 36 Colpitis Inflammatory 
changes
5
179 GIRIJA 23 20 1 12 Normal Study Inflammatory 
changes
5
180 SASIKALA 22 20 1 10 Normal Study Inflammatory 
changes
4
181 SARASWATHY 25 22 1 24 Colpitis Inflammatory 
changes
3
182 JOTHI 29 20 2 12 Normal Study Inflammatory 
changes
4
183 SHAMEEM 21 18 1 12 Normal Study Inflammatory 
changes
3
184 SAKTHI 23 20 1 12 Normal Study Inflammatory 
changes
4
185 VIJAYA 35 22 2 24 Normal Study Inflammatory 
changes
4
186 DHARANI 26 23 1 18 Normal Study Inflammatory 
changes
3
187 UMA 22 20 1 12 Normal Study Normal Study 3
188 AMBIKA 36 22 2 24 Ectopy Inflammatory 
changes
4
189 LAKSHMI 22 20 1 12 Normal Study Inflammatory 
changes
4
190 ASHMATH 21 19 1 12 Normal Study Inflammatory 
changes
4
191 GIRIJA 38 23 36 12 Colpitis Inflammatory 
changes
5
192 MAHALAKSHMI 30 21 2 18 Colpitis Inflammatory 
changes
4
193 PARAMESWARI 25 22 1 18 Normal Study Inflammatory 
changes
4
194 INDIRANI 22 20 1 12 Normal Study Normal Study 5
195 KAMATCHI 36 20 3 18 HSIL LSIL 4
196 LALITHA 21 19 1 10 Normal Study Normal Study 5
197 SUMATHI 28 22 1 24 Normal Study Inflammatory 
changes
4
198 SAKUNTHALA 25 22 1 12 Normal Study Inflammatory 
changes
5
199 KAMURINEESA 33 24 2 24 Normal Study Inflammatory 
changes
4
200 AMUDHA 29 20 2 18 Colpitis Inflammatory 
changes
5
201 FATHIMA 23 21 1 12 Colpitis Inflammatory 
changes
5
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COLPOSCOPIC 
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Economic 
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202 BHAVANI 21 19 1 10 Normal Study Normal Study 5
203 PARVATHY 26 22 1 24 Colpitis Inflammatory 
changes
5
204 SAMEEM 21 19 1 12 Normal Study Normal Study 5
205 NAGESWARI 26 22 1 18 Normal Study Inflammatory 
changes
4
206 MAHARANI 20 18 1 12 Normal Study Inflammatory 
changes
4
207 ASMATH BEGUM 27 20 2 12 Colpitis Inflammatory 
changes
4
208 KAVITHA 23 20 1 12 Normal Study Inflammatory 
changes
4
209 SUGUNA 24 21 1 18 Colpitis Inflammatory 
changes
4
210 DEEPA 24 21 1 18 Normal Study Inflammatory 
changes
5
211 CHITRA 28 20 2 12 Normal Study Normal Study 4
212 PUNITHA 23 20 1 18 Colpitis Inflammatory 
changes
4
213 THULASI 41 19 3 24 LSIL LSIL 5
214 NALINI 20 18 1 8 Normal Study Normal Study 4
215 KALIAMMAL 26 20 2 12 Normal Study Inflammatory 
changes
5
216 GEETHA 22 20 1 12 Normal Study Inflammatory 
changes
4
217 UMAMAHESWARI 21 19 1 12 Normal Study Inflammatory 
changes
5
218 DHILSHATH 28 20 2 18 Colpitis Inflammatory 
changes
4
219 VIJAYALAKSHMI 26 24 1 12 Normal Study Normal Study 4
220 SHANTHALAKSHMI 21 19 1 12 Normal Study Inflammatory 
changes
3
221 RAJESWARI 30 23 2 18 Normal Study Inflammatory 
changes
3
222 YESODADEVI 28 25 1 12 Ectopy Inflammatory 
changes
4
223 PONNI 21 18 1 12 Normal Study Normal Study 5
224 REAS BEGUM 21 18 1 12 Normal Study Inflammatory 
changes
5
225 RENUKA 23 20 2 18 Normal Study Inflammatory 
changes
5
226 VALLIAMMAL 25 23 1 12 Colpitis Inflammatory 
changes
5
227 JAYA 22 20 1 10 Normal Study Inflammatory 
changes
4
228 RAMANI 26 23 1 24 Colpitis Inflammatory 
changes
4
229 DILSHA 23 20 1 12 Normal Study Normal Study 4
230 BHARATHI 21 19 1 8 Normal Study Inflammatory 
changes
4
231 MEENA 23 20 1 12 Normal Study Normal Study 5
232 FATHIMA 21 19 1 8 Normal Study Inflammatory 
changes
5
233 MYTHILI 26 23 2 24 Colpitis Inflammatory 
changes
5
234 JEBAMARY 28 20 1 12 Normal Study Inflammatory 
changes
5
235 KAYALVIZHI 25 22 1 18 Normal Study Inflammatory 
changes
4
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236 REVATHY 21 19 1 8 Colpitis Inflammatory 
changes
4
237 RIYAZ 21 19 1 10 Normal Study Inflammatory 
changes
4
238 VASUKI 32 20 1 24 Ectopy Inflammatory 
changes
4
239 USHA 25 22 1 12 Normal Study Inflammatory 
changes
5
240 KANAKA 23 21 1 12 Normal Study Inflammatory 
changes
5
241 RANI 30 20 2 18 Colpitis Inflammatory 
changes
5
242 SUMATHI 27 23 2 18 Normal Study Inflammatory 
changes
5
243 SHAHIN 27 19 1 18 Normal Study Inflammatory 
changes
4
244 DEVIKA 25 22 1 18 Normal Study Inflammatory 
changes
4
245 BARKAT BANU 21 19 1 12 Normal Study Inflammatory 
changes
4
246 JAMUNA 25 22 1 18 Colpitis Inflammatory 
changes
4
247 SANGEETHA 20 18 1 10 Normal Study Inflammatory 
changes
5
248 LATHA 25 23 1 12 Normal Study Inflammatory 
changes
5
249 JAYANTHI 21 19 1 12 Normal Study Inflammatory 
changes
5
250 SARALA 22 19 1 18 Colpitis Inflammatory 
changes
5
251 SHAMEEM 19 17 1 8 Normal Study Normal Study 4
252 KAVITHA 23 20 1 12 Normal Study Inflammatory 
changes
4
253 MALINI 26 22 1 24 Colpitis Inflammatory 
changes
4
254 MALA 30 20 2 18 Normal Study Inflammatory 
changes
4
255 KAVITHA 31 21 2 24 Normal Study Inflammatory 
changes
5
256 SATHYA 20 18 1 10 Normal Study Inflammatory 
changes
5
257 MUMTAJ 20 18 1 8 Normal Study Normal Study 5
258 SHEELA 34 20 2 24 Colpitis Inflammatory 
changes
5
259 VASANTHI 23 20 1 18 Normal Study Inflammatory 
changes
4
260 RASHITHA 21 19 1 12 Normal Study Inflammatory 
changes
4
261 SHANTHI 27 20 2 12 Normal Study Inflammatory 
changes
4
262 BABY 27 19 2 18 Normal Study Inflammatory 
changes
4
263 VIJAYA 35 28 1 24 Ectopy Inflammatory 
changes
4
264 JAMEELA 22 20 1 12 Normal Study Normal Study 5
265 SHAKILA 21 19 1 8 Normal Study Inflammatory 
changes
5
266 VEERALAKSHMI 24 21 1 12 Normal Study Inflammatory 
changes
5
S.No Name Age Age At 
Marriage
Number of 
Children
Duration of 
Cu T use in 
Months
COLPOSCOPIC 
CHANGES
CYTOLOGY Socio 
Economic 
Status
267 JAMEELA 19 17 1 8 Colpitis Inflammatory 
changes
5
268 ANUSHYA 23 21 1 12 Normal Study Inflammatory 
changes
4
269 JAMUNA BEGUM 27 20 2 18 Normal Study Normal Study 4
270 JAI BANU 22 20 1 12 Normal Study Inflammatory 
changes
4
271 NALINI 25 22 1 18 Colpitis Inflammatory 
changes
4
272 JAYANTHI 22 20 1 12 Normal Study Normal Study 5
273 BINDU 22 19 1 18 Colpitis Inflammatory 
changes
5
274 GEETHA 21 19 1 10 Normal Study Inflammatory 
changes
5
275 MUMTAJ 21 18 1 12 Normal Study Normal Study 5
276 JAYANTHI 22 20 1 12 Normal Study Inflammatory 
changes
4
277 USHA RANI 22 19 1 18 Colpitis Inflammatory 
changes
4
278 MAHESWARI 25 22 1 24 Normal Study Inflammatory 
changes
4
279 NAJIMUNIEESHA 27 19 2 24 Normal Study Inflammatory 
changes
4
280 FATHIMA 25 23 1 36 Ectopy Inflammatory 
changes
5
281 ALAMELU 21 19 1 12 Normal Study Inflammatory 
changes
5
282 SIKANTHAR 21 19 1 12 Colpitis Inflammatory 
changes
5
283 SAVITHA 28 20 2 18 Normal Study Inflammatory 
changes
5
284 GOWRI 22 20 1 12 Colpitis Inflammatory 
changes
4
285 SATHYA 23 20 1 18 Normal Study Inflammatory 
changes
4
286 JAYABARATHI 31 19 3 18 Ectopy Inflammatory 
changes
4
287 LATHA 28 18 2 36 Colpitis Inflammatory 
changes
4
288 MALA 24 22 1 12 Colpitis Inflammatory 
changes
5
289 SHERLY 19 17 1 8 Normal Study Normal Study 5
290 MAHALAKSHMI 20 19 1 12 Normal Study Inflammatory 
changes
5
291 MOHANA 24 20 1 18 Colpitis Normal Study 5
292 KALIYAMMA 26 20 2 10 Normal Study Inflammatory 
changes
4
293 MARY 23 20 1 18 Colpitis Normal Study 4
294 JESIMA BEGUM 20 18 1 12 Normal Study Inflammatory 
changes
4
295 SUMATHI 23 20 1 18 Normal Study Inflammatory 
changes
4
296 JANSI RANI 26 23 1 24 Normal Study Inflammatory 
changes
5
297 SUMITHA 21 18 1 18 Normal Study Inflammatory 
changes
5
298 VANATHI 23 20 1 12 Normal Study Inflammatory 
changes
4
GLOSSARY
IUD  -Intrauterine contraceptive Device  
CuT-Copper T copper wire wound round the vertical limb
WHO  - World Health Organisation  
NSAIDS-Non-Steroidal Antiinflammatory  Drugs
PID-Pelvic Inflammatory Disease
ML Cu250-Multi Load Copper realizing device with 250 sq. mm. of exposed 
copper  the  form of  wire  wrapped  around  the  vertical  shaft  .The  arms  are 
flexible plastic serrated fins.
STI-sexually Transmitted Infection 
LNG 20-Levonorgesterol Intrauterine contraceptive device/releases 20 micro 
gm per day.
ASCUS-Atypical Squamous Cells of Undetermined Significance
CIN-Cervical Intraepithelial Neoplasia
BCC-Benign Cellular Changes
LSIL-Low Grade Squamous Intraepithelial Lesion
HSIL-High Grade Squamous Intraepithelial Lesion
CuT380 A-‘T’ shaped and have 314 square mm copper wire on the vertical 
stem and 33 sqaure mm copper sleeves on each of the two transverse arms
CuT200-‘T’ shaped device made of polypropylene and carries 120 milligram 
of copper wire wound round the vertical limb
CYTOLOGY PICTURES
Actinomyces – Typical aggregates of pseudo filamentous material – 
smear from a women with IUD
Pap Smear – Inflammatory changes. Morphological changes 
frequently seen affecting parabasal metaplastic cells in women 
using IUD
